| Mon 16 March
|
|
09:00 10:45
|
|
Registration
Main foyer
|
| |
|
|
|
10:45 12:15
|
|
PCOS Special Interest Group Satellite: Major scientific and clinical issues in PCOS
Generously supported by Almirall Ltd
Main auditorium
Chairs: S Atkin (Hull) & H Randeva (Warwick)
|
| 10:45 |
|
Androgens and human hair growth
V Randall (Bradford)
|
| 11:15 |
|
Insulin resistance and fatty acid metabolism in PCOS
D Sandeman (Southampton)
|
| 11:45 |
|
Female libido and PCOS
H Buckler (Manchester)
|
| |
|
|
|
10:45 12:15
|
|
Pituitary Special Interest Group Satellite: Cushing's disease: present and future
Queen's Suite 2
Chairs: R Murray (Leeds) & R Fowkes (London)
|
| 10:45 |
|
Welcome
R Murray (Leeds)
|
| 10:50 |
|
The molecular pathogenesis of corticotroph tumors
A Grossman (London)
|
| 11:15 |
|
Current therapeutic modalities: roles and limitations
J Newell-Price (Sheffield)
|
| 11:40 |
|
New Therapies: potential new medical therapies
B Atkinson (Belfast)
|
| 12:00 |
|
New therapies: is there a future for siRNA in management of Cushing's?
J Newell-Price (Sheffield)
|
| |
|
|
|
10:45 12:15
|
|
Andrology Special Interest Group Satellite: Recent advances in andrology
Generously supported by Bayer Schering Pharma
Queen's Suite 1
Chairs: H Jones (Barnsley) & F Wu (Manchester)
|
| 10:45 |
|
Androgens and bone
D Vanderschueren (Leuven, Belgium)
|
| 11:15 |
|
Molecular genetics of Kallmann’s syndrome and IHH
P Bouloux (London)
|
| 11:45 |
|
Testosterone and cardiovascular disease
H Jones (Barnsley)
|
| |
|
|
|
12:15 13:00
|
|
Lunch
Hall Q
|
| |
|
|
|
13:00 15:00
|
|
Symposium 1: Finding the right balance of dietary and metabolic influences in fetal and adult life
Nutritional and environmental factors in early life influence endocrine function in adult life
Queen's Suite 1
Chairs: M Symonds (Nottingham) & B Kola (London)
|
| 13:00 |
S10
|
Glucocorticoids, chronic stress, and obesity
M Dallman (San Francisco, USA)
|
| 13:30 |
S11
|
Transgenerational programming of the glucocorticoid axis and maternal stress
A Drake (Edinburgh)
|
| 14:00 |
S12
|
Maternal undernutrition and endocrine development
M Hanson (Southampton)
|
| 14:30 |
S13
|
The fetal cost of maternal cafeteria diets
N Stickland (London)
|
| |
|
|
|
13:00 15:00
|
|
Clinical Management Workshop 1: Measuring hormones: what does your result mean?
What every clinical endocrinologist needs to know
Supported by the Clinical Endocrinology
Main Auditorium
Chairs: S Ball (Newcastle-upon-Tyne) & E Murphy (London)
|
| 13:00 |
S46
|
What service does the laboratory provide?
J Barth (Leeds)
|
| 13:30 |
S47
|
Is what is normal for me normal for you?
G Wieringa (Manchester)
|
| 14:00 |
S48
|
What new tests are on the horizon?
G Beastall (Glasgow)
|
| 14:30 |
S49
|
Interpreting results: a Clinician’s perspective
S Shalet (Manchester)
|
| |
|
|
|
13:00 15:00
|
|
Applied Physiology Workshop: Metabolic phenotyping in human endocrine disorders
Queen's Suite 2
Chairs: M Gurnell (Cambridge) & J Wells (London)
|
| 13:00 |
S77
|
Characterising over consumption: appetite expression and food choice
J Halford (Liverpool)
|
| 13:30 |
S78
|
Limitations of DEXA as a measure of body composition
J Wells (London)
|
| 14:00 |
S79
|
The hyperinsulinaemic euglycaemic clamp and stable isotope methodology for in-vivo physiological studies
H Simpson (Cambridge)
|
| 14:30 |
S80
|
Magnetic Resonance Spectroscopy – a window into carbohydrate and lipid metabolism
D Savage (Cambridge)
|
| |
|
|
|
15:00 15:30
|
|
Coffee
|
| |
|
|
|
15:30 17:30
|
|
Symposium 2: Calcium conundrums: too high, too low and what to do
Hyper and hypocalcaemia are common and important endocrine problems. This symposium will cover presentation, diagnosis and management of common disorders of calcium metabolism.
Queen's Suite 1
Chairs: J Walsh (Sheffield) & R Lindsay (New York, USA)
|
| 15:30 |
S14
|
Management of severe hypercalcaemia
D Hosking (Nottingham)
|
| 16:00 |
S15
|
Diagnosis and management of post-operative hypocalcaemia following (para)thyroidectomy
N Gittoes (Birmingham)
|
| 16:30 |
S16
|
Familial benign hypocalciuric hypercalcaemia (FHH) – an update
K Brixen (Odense, Denmark)
|
| 17:00 |
S17
|
Mild hyperparathyroidism: to treat or not to treat, that is the question
R Mihai (Oxford)
|
| |
|
|
|
15:30 17:30
|
|
Oral Communications 1: Young Endocrinologists prize session
Main auditorium
Chairs: J Wass (Oxford) & N Morton (Edinburgh)
|
| 15:30 |
OC1
|
Alternative splicing of the thyroid hormone receptor α gene regulates skeletal development
T Galliford;
A Ghaffar;
J Bassett;
G Williams;
|
| 15:45 |
OC2
|
Anti-inflammatory effects of 5 alpha-reduced glucocorticoids in vitro and in vivo
C Yang;
A Rossi;
R Duffin;
D Livingstone;
C Kenyon;
B Walker;
R Andrew;
|
| 16:00 |
OC3
|
The Role of Glucocorticoid Metabolism in Osteosarcoma Pathogenesis and Treatment
P Patel;
R Hardy;
N Gittoes;
E Rabbitt;
L Kindblom;
P Stewart;
M Cooper;
|
| 16:15 |
OC4
|
KISSPEPTIN POTENTLY INCREASES REPRODUCTIVE HORMONE RELEASE IN WOMEN WITH HYPOTHALAMIC AMENORRHOEA – A POTENTIAL NOVEL THERAPY FOR INFERTILITY
C Jayasena;
O Chaudhri;
G Nijher;
K Murphy;
A Ranger;
A Lim;
D Patel;
A Mehta;
C Todd;
R Ramachandran;
V Salem;
G Stamp;
M Donaldson;
M Ghatei;
S Bloom;
W Dhillo;
|
| 16:30 |
OC5
|
Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves insulin sensitivity in skeletal muscle through modulation of IRS1 serine phosphorylation
S Morgan;
L Gathercole;
G Lavery;
M Sherlock;
I Bujalska;
J Sethi;
K Hegyi;
P Stewart;
D Smith;
J Tomlinson;
|
| 16:45 |
OC6
|
Locally generated glucocorticoids, rather than pro-inflammatory cytokines, directly regulate synovial DKK-1 expression in inflammatory arthritis
R Hardy;
M Ahasan;
P Patel;
A Filer;
E Rabbitt;
K Raza;
P Stewart;
C Buckley;
M Cooper;
|
| 17:00 |
OC7
|
In Vivo and Ex Vivo Regulation of Visfatin Production by Leptin in Human and Murine Adipose Tissue: Role of the PI3K and MAPK Pathways
B Tan;
J Chen;
J Brown;
R Adya;
M Ramanjaneya;
C Bailey;
H Lehnert;
H Randeva;
|
| 17:15 |
OC8
|
Quality of life (QoL) in male and female patients with congenital adrenal hyperplasia (CAH) compared to healthy subjects and patients with primary adrenal insufficiency
B Bleicken;
S Hahner;
M Loeffler;
M Ventz;
B Allolio;
M Quinkler;
|
| |
|
|
|
15:30 17:30
|
|
Oral Communications 2: Neuroendocrine and steriods
Queen's Suite 2
Chairs: J Connell (Glasgow) & V Sharp (London)
|
| 15:30 |
OC9
|
11 beta-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVITY LIMITS FIBROSIS FOLLOWING BLEOMYCIN LUNG INJURY BY AUGMENTING ACTIVE GLUCOCORTICOIDS
F Yang;
R Duffin;
D Brownstein;
A Coutinho;
A Rossi;
J Savill;
J Seckl;
K Chapman;
|
| 15:45 |
OC10
|
PAPSS2 Deficiency: A novel monogenic cause of androgen excess
V Dhir;
C Noordam;
J McNelis;
F Schlereth;
N Hanley;
N Krone;
J Smeitink;
R Smeets;
F Sweep;
H Claahsen-van der Grinten;
W Arlt;
|
| 16:00 |
OC11
|
Familial and Phenotypic Associations of the Aldosterone Renin Ratio in the General Population
S Alvarez-Madrazo;
S Padmanabhan;
M Wallace;
M Campbell;
J Smith;
E Friel;
C Dorrian;
B Keavney;
E Davies;
J Connell;
|
| 16:15 |
OC12
|
Absence of hexose-6-phosphate dehydrogenase specifically induces skeletal myopathy in mice
N Semjonous;
G Lavery;
E Walker;
P Stewart;
|
| 16:30 |
OC13
|
Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 promotes intra-retinal vascularisation in a murine model of ischaemic retinopathy.
A Dover;
A Stitt;
C McVicar;
C Kitson;
P Hadoke;
B Walker;
|
| 16:45 |
OC14
|
Urinary steroid profiling as a biomarker tool for the detection of adrenal malignancy – Results of the EURINE ACC Study
W Arlt;
S Hahner;
R Libe;
B Hughes;
M Biehl;
H Stiekema;
P Schneider;
D Smith;
C Shackleton;
G Opocher;
J Bertherat;
B Allolio;
M Mannelli;
F Mantero;
M Fassnacht;
X Bertagna;
P Stewart;
|
| 17:00 |
OC15
|
Identification of the gene for FGD type 3 on chromosome 8
L Metherell;
D Naville;
M Begeot;
A Huebner;
M Racine;
G Halaby;
A Clark;
|
| 17:15 |
OC16
|
Immunohistochemical Evidence that Argillin, the Product of the ECRG4 Gene, Encodes a Novel Neuroendocrine Peptide
A Roberton;
A Gonzalez;
E Stopa;
W Leadbeater;
R Coimbra;
C Johanson;
B Eliceiri;
A Baird;
|
| |
|
|
|
17:30 17:45
|
|
Tea
Hall Q
|
| |
|
|
|
17:45 18:25
|
|
Young Endocrinologist Prize Lectures
Main Auditorium
Chairs: P Trainer (Manchester) & M Korbonits (London)
|
| 17:45 |
S71
|
In search of the genetic basis of polycystic ovary syndrome and its metabolic consequences
T Barber (Oxford)
|
| 18:05 |
S72
|
An anti-inflammatory role of interleukin-4 in the human ovarian surface epithelium
G Papacleovoulou (Edinburgh)
|
| |
|
|
|
18:25 18:55
|
|
Society for Endocrinology Jubilee Medal Lecture
Main auditorium
Chair: D Ray (Manchester)
|
|
S1
|
Per ardua ad pituita - more than just phlegm
J Wass (Oxford)
|
| |
|
|
|
19:00
|
|
Welcome Reception
Join us to celebrate the 70th anniversary of Journal of Endocrinology
|
| |
|
|
|
19:45
|
|
Young Endocrinologists' Quiz Night
Hall D
|
| |
|
|
| Tue 17 March
|
|
07:15 08:00
|
|
Clinical Expert 1: Thyroid eye disease (clinical evaluation and classification – EUGOGO)
P Perros (Newcastle-upon-Tyne)
Supported by Clinical Endocrcinology
Queen's Suite 1
Chair: M Vanderpump (London)
|
| |
|
|
|
07:15 08:00
|
|
Clinical Expert 2: Delayed puberty
J Kirk (Birmingham)
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: J Wales (Sheffield)
|
| |
|
|
|
08:15 10:15
|
|
Symposium 3: What's WNT? - a novel signaling pathway in endocrinology
Although widely established as a critical regulator of development, the Wnt signaling pathway has only recently been identified as a major regulator of endocrine cell function.
Queen's Suite 1
Chairs: M Dattani (London) & R Fowkes (London)
|
| 08:15 |
S18
|
Wnt signaling and its role in adrenal cancer
G Hammer (Ann Arbor, USA)
|
| 08:45 |
S19
|
Targeting mediators of Wnt signalling by GnRH
A Pawson (Edinburgh)
|
| 09:15 |
S20
|
Defects in Wnt signalling in hyperparathyroidism
G Westin (Uppsala, Sweden)
|
| 09:45 |
S21
|
Paracrine signalling in the ovary: the role of Wnt
D Boerboom (Québec, Canada)
|
| |
|
|
|
08:15 10:15
|
|
Oral Communications 3: Cardiovascular metabolism
Queen's Suite 2
Chairs: R Stimson (Edinburgh) & E Davies (Glasgow)
|
| 08:15 |
OC17
|
Effect of Single High vs Low Glycemic Index (GI) Meal on Gut Hormones.
A Norouzy;
A Leeds;
P Emery;
I Bayat;
|
| 08:30 |
OC18
|
Non Alcoholic Fatty Liver Disease is associated with increased 5 alpha-reductase expression and activity and consequent HPA-axis activation.
A Ahmed;
J Tomlinson;
J Dowman;
P Newsome;
E Elias;
A Wagenmakers;
P Stewart;
|
| 08:45 |
OC19
|
Glucocorticoid and Insulin Regulation of Lipogenesis in Human Adipose Tissue
L Gathercole;
I Buljalska;
P Stewart;
J Tomlinson;
|
| 09:00 |
OC20
|
THE NOVEL PEPTIDE PROKINETICIN-2 POTENTLY INHIBITS FOOD INTAKE IN RODENTS AND IS A POTENTIAL NOVEL ANTI-OBESITY THERAPY
A Bataveljic;
J Gardiner;
N Patel;
G Bewick;
D Roy;
J Cooke;
D Campbell;
N Semjonous;
K Murphy;
S Hameed;
H Prosser;
P Jethwa;
F Ebling;
S Vickers;
S Cheetham;
P Maleuwe;
M Ghatei;
S Bloom;
W Dhillo;
|
| 09:15 |
OC21
|
Cerebellin1 is a novel orexigenic factor which potently increases food intake via hypothalamic neuropeptide Y release.
D Roy;
W Dhillo;
J Gardiner;
A Bataveljic;
D Campbell;
N Patel;
M Ghatei;
S Bloom;
|
| 09:30 |
OC22
|
The effects of ghrelin and cannabinoids on AMP-activated protein kinase (AMPK) activity in growth hormone-secretagogue receptor (GHS-R) knockout mice
C Lim;
B Kola;
D Feltrin;
D Perez-Tilve;
A Grossman;
M Tschop;
M Korbonits;
|
| 09:45 |
OC23
|
Insulin Increases and Metformin Decreases the Novel Adipokine Chemerin in Insulin Resistant Subjects: PCOS as a Paradigm
B Tan;
J Chen;
R Adya;
J Kaur;
D Heutling;
K CLewandowski;
H Lehnert;
H Randeva;
|
| 10:00 |
OC24
|
Metformin improves arterial stiffness and endothelial function in young women with PCOS: a randomised, crossover trial
N Agarwal;
S Rice;
H Bolusani;
R Newcombe;
M Ludgate;
A Rees;
|
| |
|
|
|
08:15 10:15
|
|
Clinical Management Workshop 2: Improving mortality and morbidity in pituitary disease
Patients suffer and die early after treatment of pituitary disease-How to improve outcomes
Supported by the Clinical Endocrinology
Main Auditorium
Chairs: J Ahlquist (Southend) & V Moyes (London)
|
| 08:15 |
S50
|
Mortality in patients with pituitary disease
J Newell-Price (Sheffield)
|
| 08:45 |
S51
|
Does hormone replacement normalise life expectancy?
W Drake (London)
|
| 09:15 |
S52
|
Why craniopharyngioma remains a condition with a high mortality and morbidity?
N Karavitaki (Oxford)
|
| 09:45 |
S53
|
Adverse outcomes following pituitary radiotherapy
J Ayuk (Birmingham)
|
| |
|
|
|
10:15 10:45
|
|
Coffee
Hall Q
|
| |
|
|
|
10:40 10:45
|
|
What the Research Network can do for you
|
|
|
J Wilding (Liverpool)
|
| |
|
|
|
10:45 11:25
|
|
Society for Endocrinology Dale Medal Lecture
Main auditorium
Chair: J Wass (Oxford)
|
|
S2
|
Healthspan: How far can it be extended into aging?
M Thorner (Charlottesville, USA)
|
| |
|
|
|
11:25 11:30
|
|
New funding opportunities for biochemical and clinical research
UK research funding has recently been reorganised to ensure that there are opportunities for all researchers in basic science, translational medicine and clinical trials. These will be discussed
Main Auditorium
|
|
|
R Thakker (Oxford)
|
| |
|
|
|
11:30 12:00
|
|
Society for Endocrinology Transatlantic Medal Lecture
Main auditorium
Chair: J Wass (Oxford)
|
|
S3
|
Estrogen action: two decades of humbling predictions
L Jameson (Chicago, USA)
|
| |
|
|
|
12:00 13:30
|
|
Lunch and posters
Hall Q
|
| |
|
|
|
13:30 15:30
|
|
Symposium 4: What is the TSH set point? Does it matter in clinical disease?
Your TSH level: nature, nurture and misadventure
Main auditorium
Chairs: G Williams (London) & M Gurnell (Cambridge)
|
| 13:30 |
S22
|
Physiological determination of HPT axis
R Weiss (Chicago, USA)
|
| 14:00 |
S23
|
Genetic determinants of HPT axis set point
R Peeters (Rotterdam, Netherlands)
|
| 14:30 |
S24
|
Abnormalities of HPT axis – lessons from paediatric endocrinology
T Cheetham (Newcastle-upon-Tyne)
|
| 15:00 |
S25
|
Pathological conesquences of altered HPT axis set-point; sub-clinical thyroid disease?...
S Pearce (Newcastle-upon-Tyne)
|
| |
|
|
|
13:30 15:30
|
|
Oral Communications 4: Bone and calcium
Queen's Suite 1
Chairs: R Eastell (Sheffield) & S Khaana (Glasgow)
|
| 13:30 |
OC25
|
Genome-wide Abnormalities in Parental Inheritance Patterns and DNA Methylation in Russell-Silver Syndrome
R Dias;
I Bogdarina;
L Johnston;
C Buchanan;
M Savage;
A Hokken-Koelega;
A Clark;
|
| 13:45 |
OC26
|
Primary Hyperparathyroidism (Nationwide Cohort Study): An increased risk of cancer and decreased survival
S GHOSH;
A COLLIER;
D CLARK;
T ELHADD;
I MALIK;
|
| 14:00 |
OC27
|
Adipokines may modify osteoblast wnt-signalling through dickkopf-1, and promote osteoclastogenesis by altering RANK-L and osteoprotegerin signalling in obese children.
P Dimitri;
J Wales;
N Bishop;
|
| 14:15 |
OC28
|
Novel Glial Cells Missing B (GCMB) mutations (Arg39Stop and Arg110Trp) that result in loss of subcellular localization and DNA binding, respectively, are associated with autosomal recessive hypoparathyroidism
M Bowl;
S Mirczuk;
T Cranston;
S Bahl;
J Allgrove;
M Nesbit;
R Thakker;
|
| 14:30 |
OC29
|
Nuf mice with an activating calcium sensing receptor mutation, Leu723Gln, have hypercalciuria and diabetes insipidus
F Hannan;
G Walls;
M Nesbit;
T Hough;
B Shine;
M Cheeseman;
M Lyon;
R Cox;
R Thakker;
|
| 14:45 |
OC30
|
Mice deleted for the Hyperparathyroidism-Jaw Tumour (HPT-JT) syndrome allele have abnormal parathyroids with increased proliferation rates.
G Walls;
M Bowl;
J Jeyabalan;
A Reed;
B Harding;
A Ali;
K Bradley;
P Wang;
J Chen;
B Williams;
B Teh;
R Thakker;
|
| 15:00 |
OC31
|
A mouse with a Trp589Arg mutation in N-acetylgalactosaminyltransferase 3 (Galnt3) provides a model for familial tumoural calcinosis
C Esapa;
R Head;
C Chan;
E Crane;
M Cheeseman;
T Hough;
E McNally;
A Carr;
G Thomas;
M Brown;
P Croucher;
S Brown;
R Cox;
R Thakker;
|
| 15:15 |
OC32
|
Human primary cytotrophoblasts from normal and IUGR pregnancies respond differently to T3 treatment in vitro
E Vasilopoulou;
L Loubière;
C McCabe;
J Franklyn;
M Kilby;
S Chan;
;
|
| |
|
|
|
13:30 15:30
|
|
Young Endocrinologists' Symposium: The ‘how-to’ guide on scientific communication
A skills based session covering all aspects of written and oral scientific communication skills necessary for all Young Endocrinologists today
Queen's Suite 2
Chairs: K Jonas (London) & K Forbes (Manchester)
|
| 13:30 |
S73
|
How to write a scientific paper
J Davis (Manchester)
|
| 14:00 |
S74
|
Conference presentations – how to engage your audience.
T Michael (London)
|
| 14:30 |
S75
|
Poster presentations: from poster layout to data presentation
G Lavery (Birmingham)
|
| 15:00 |
S76
|
Scientific networking - how to make the most of networking opportunities
S Hillier (Edinburgh)
|
| |
|
|
|
15:30 16:00
|
|
Tea
Hall Q
|
| |
|
|
|
16:00 17:00
|
|
Clinical Debate: This house believes that radioactive iodine is the first line of treatment for Graves' disease
Main audtorium
Chair: J Franklyn (Birmingham)
|
|
|
For: K Meeran (London)
|
|
|
Against: W Wiersinga (Amsterdam, Netherlands)
|
| |
|
|
|
16:00 17:00
|
|
Clinical Expert 1 repeat: Thyroid eye disease (clinical evaluation and classification – EUGOGO)
P Perros (Newcastle-upon-Tyne)
Supported by Clinical Endocrinology
King's Suite
Chair: M Vanderpump (London)
|
| |
|
|
|
16:00 18:00
|
|
Oral Communications 5: Thyroid, reproduction and endocrine tumours
Queen's Suite 1
Chairs: C Dayan (Bristol) & K Jonas (London)
|
| 16:00 |
OC33
|
Thyrotropin Receptor (TSHR) Activation Increases Hyaluronan (HA) Production in Preadipocyte-Fibroblasts; Explanation for HA Accumulation in Thyroid Dysfunction?
L Zhang;
T Bowen;
C Paddon;
J Webber;
P Giles;
R Steadman;
M Ludgate;
|
| 16:15 |
OC34
|
Reduction of type I 5'-iodothyronine deiodinase activity and mRNA level in renal clear cell carcinoma (ccRCC): potential role of 3’ UTR and miRNA.
J Boguslawska;
A Master;
A Piekielko-Witkowska;
A Wojcicka;
I Brozda;
P Poplawski;
A Macke-Nauman;
|
| 16:30 |
OC35
|
Bio-informatic identification of novel endocrine markers of gestational disease in the human placenta
V Karanam;
N Anim-Nyame;
N Page;
|
| 16:45 |
OC36
|
Spatio-temporal expression of bone morphogenetic protein (BMP) antagonists during early follicle development
M Fenwick;
S Franks;
J Stark;
K Hardy;
|
| 17:00 |
OC37
|
Elderly patients presenting with hyperthyroidism have a paucity of symptoms and signs – a cross-sectional study of 3563 UK patients
K Boelaert;
B Torlinska;
J Franklyn;
|
| 17:15 |
OC38
|
Bone morphogenetic protein-2 and -4 enhance FSH-induced p38 activation leading to upregulation of estradiol production through oocyte-granulosa cell interaction
T Miyoshi;
F Otsuka;
K Inagaki;
M Yamashita;
J Goto;
N Tsukamoto;
M Takeda;
J Suzuki;
H Makino;
|
| 17:30 |
OC39
|
Contrasting clinical manifestations of SDH-B and VHL associated chromaffin tumours.
U Srirangalingam;
B Khoo;
L Walker;
F MacDonald;
R Skelly;
E George;
D Spooner;
L Johnston;
J Monson;
A Grossman;
S Akker;
W Drake;
P Pollard;
N Plowman;
N Avril;
D Berney;
J Burrin;
R Reznek;
V Kumar;
E Maher;
S Chew;
|
| 17:45 |
OC40
|
THE CLINICAL AND GENETIC CHARACTERISTICS OF PATIENTS WITH FAMILIAL ISOLATED PITUITARY ADENOMA
H Chahal;
S Igreja;
M Gueorguiev;
R Quinton;
J Wass;
V Popovic;
A Ribeiro-Oliveira Jr;
J Monson;
S Akker;
P Gallego;
S Orme;
A Goldstone;
J Bevan;
T Cheetam;
J Davis;
R Clayton;
D Flanagan;
L Frohman;
A Grossman;
M Korbonits;
|
| |
|
|
|
16:00 18:00
|
|
Symposium 5: The endoplasmic reticulum – an important link between inflammation, stress and diabetes
The endoplasmic reticulum has recently emerged as a key organelle responsive to cellular stress with critical roles in metabolism and immune responses. Here, its role in these processes is addressed.
Queen's Suite 2
Chairs: K Chapman (Edinburgh) & G Lavery (Birmingham)
|
| 16:00 |
S26
|
Endoplasmic reticulum: inflammation, obesity and diabetes
R Kaufman (Ann Arbor, USA)
|
| 16:30 |
S27
|
Regulation of hepatic lipid metabolism: interplay between insulin and the endoplasmic reticulum
P Ferre (Paris, France)
|
| 17:00 |
S28
|
The endoplasmic reticulum as a metabolic compartment
G Banhegyi (Budapest, Hungary)
|
| 17:30 |
S29
|
Glucose sensing in the endoplasmic reticulum: maintaining the cellular environment
G Lavery (Birmingham)
|
| |
|
|
|
17:00 18:00
|
|
Clinical Expert 2 repeat: Delayed puberty
J Kirk (Birmingham)
Suppported by Clinical Endocrinology
King's Suite
Chair: J Wales (Sheffield)
|
| |
|
|
|
18:00 19:15
|
|
The future delivery of endocrine care in the NHS - have your say
An opportunity for you to learn how the Society's Clinical Committee has been responding to recent consultations on how endocrine care will be delivered in the NHS and allow members of the audience to comment on how best the Society can continue to represent the views of its membership.
Chair: P Trainer (Manchester), Chair of the Society's Clinical Committee
|
| |
|
|
|
19:30
|
|
Conference dinner
Majestic hotel
|
| |
|
|
| Wed 18 March
|
|
07:15 08:00
|
|
Clinical Expert 3: Turner Syndrome - how to smooth the transition between paediatric and adult clinic
M Davies (London)
Generously supported by Ipsen Ltd
Queen's Suite 1
Chair: G Conway (London)
|
| |
|
|
|
07:15 08:00
|
|
Clinical Expert 4: Vitamin D deficiency, diagnosis and management
Z Mughal (Manchester)
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: P Selby (Manchester)
|
| |
|
|
|
08:10 08:55
|
|
Society for Endocrinology Annual General Meeting
Main auditorium
|
| |
|
|
|
09:00 11:00
|
|
Symposium 6: Polycystic Ovarian Syndrome (PCOS): when does it start, why and what to do about it?
Update on why does PCOS start, PCOS in the adolescent and is there a place metforin
Main auditorium
Chairs: C Duncan (Edinburgh) & T Barber (Oxford)
|
| 09:00 |
S30
|
Searching for candidate genes: what are the players?
S Franks (London)
|
| 09:30 |
S31
|
Evolution of obesity and insulin resistance: relevance to PCOS
T Barrett (Birmingham)
|
| 10:00 |
S32
|
The teenager with polycystic ovarian syndrome
C Kelnar (Edinburgh)
|
| 10:30 |
S33
|
Metformin – a storm with few good data
K Hoeger (Rochester, USA)
|
| |
|
|
|
09:00 11:00
|
|
Symposium 7: Phosphoinositide 3- kinase (PI3K) signalling in health and disease: an old system with new potential
PI3 is a pivitol signaling molecule in the action of multiple hormone including insulin and leptin
Queen's Suite 1
Chairs: R Abayasekara (London) & L Matthews (Manchester)
|
| 09:00 |
S34
|
Signalling from cell surface receptors: molecular mechanisms and physiological significance of the phosphoinositide 3-kinase signalling system
P Hawkins (Cambridge)
|
| 09:30 |
S35
|
Disordered phosphoinositide signalling and the basis of tumour formation
N Leslie (Dundee)
|
| 10:00 |
S36
|
Insulin: role of PI3 kinase signalling in growth and metabolism – lessons from flies and mice
M Birnbaum (Philadelphia, USA)
|
| 10:30 |
S37
|
PI3 kinase inhibitors: fantasy or reality
P Workman (London)
|
| |
|
|
|
09:00 11:00
|
|
Nurses' Session 1: Sex hormone replacement
Queen's Suite 2
Chairs: M Carson (Edinburgh) & V Kieffer (Leicester)
|
| 09:00 |
S62
|
Hormone replacement therapy
H Buckler (Manchester)
|
| 09:30 |
S63
|
HRT case presentation: gonadal dysgenesis
A Webb (Cambridge)
|
| 09:45 |
S64
|
When HRT causes a headache
B McAllister (Manchester)
|
| 10:00 |
S65
|
Recent advances in male hypogonadism
F Wu (Manchester)
|
| 10:30 |
S66
|
Androgen replacement in female to male transgender
D Wright (Bradford)
|
| |
|
|
|
11:00 11:25
|
|
Coffee
Hall Q
|
| |
|
|
|
11:25 11:30
|
|
European Society of Endocrinology: Why should I be a member?
Main auditorium
|
|
|
E Nieschlag (Münster, Germany)
|
| |
|
|
|
11:30 12:05
|
|
Society for Endocrinology European Medal Lecture
Main auditorium
Chair: J Wass (Oxford)
|
|
S4
|
Early stages of thyroid autoimmunity
W Wiersinga (Amsterdam, Netherlands)
|
| |
|
|
|
12:05 12:40
|
|
Society for Endocrinology International Medal Lecture
Main auditorium
Chair: J Buckingham (London)
|
|
S5
|
Hormones and behaviour: new insights from GFP molecular imaging and neuroanatomy
M Kawata (Kyoto, Japan)
|
| |
|
|
|
12:40 14:15
|
|
Lunch and posters
Hall Q
|
| |
|
|
|
14:15 16:15
|
|
Symposium 8: Novel aspects of bone physiology in relation to osteoporosis treatment
Besides bisphosphanates there are several agents with the potential to improve the management of osteoporosis
Main auditorium
Chairs: P Selby (Manchester) & K Javaid (Oxford)
|
| 14:15 |
S38
|
New tools for the study of bone-active drugs
R Eastell (Sheffield)
|
| 14:45 |
S39
|
Bone signalling pathways – their importance in the treatment of osteoporosis
G Williams (London)
|
| 15:15 |
S40
|
Anabolic treatments in osteoporosis
R Lindsay (New York, USA)
|
| 15:45 |
S41
|
Bisphosphanates uses and abuses (including young people and duration of therapy)
A McLellan (Glasgow)
|
| |
|
|
|
14:15 16:15
|
|
Symposium 9: Kisspeptin a Novel Regulator of puberty and fertility
Kisspeptin is crucial for your first kiss
Queen's Suite 1
Chairs: L Jameson (Chicago, USA) & K Murphy (London)
|
| 14:15 |
S42
|
Kisspeptin signalling and fertility
W Colledge (Cambridge)
|
| 14:45 |
S43
|
Role of Kisspeptin in the Metabolic Regulation of Fertility
M Tena-Sempere (Cordoba, Spain)
|
| 15:15 |
S44
|
Human kisspeptin receptor mutations and puberty
S Seminara (Boston, USA)
|
| 15:45 |
S45
|
What does kisspeptin do in humans?
W Dhillo (London)
|
| |
|
|
|
14:15 16:15
|
|
Nurses' Session 2: Thyroid disease
Queen's Suite 2
Chairs: J Munday (Portsmouth) & P Pickett (Oswestry)
|
| 14:15 |
S67
|
Thyroid hormone replacement
C Dayan (Bristol)
|
| 14:45 |
S68
|
Raised TSH: hypothyroidism, poor compliance or what?
S Sharma (London)
|
| 15:15 |
S69
|
Congenital hypothyroidism
P Hindmarsh (London)
|
| 15:45 |
S70
|
Autoimmune thyroid disease with subsequent biochemical abnormalities and pregnancy
A Hawkins (London)
|
| |
|
|
|
16:15 16:45
|
|
Tea
Hall Q
|
| |
|
|
|
16:15 16:45
|
|
Nurses' Tea and poster viewing
Conference Suite
|
| |
|
|
|
16:45 16:55
|
|
Awards ceremony
Main auditorium
|
| |
|
|
|
16:55 17:30
|
|
British Thyroid Association Pitt-Rivers Lecture
Supported by the Clinical Endocrinology Trust
Main auditorum
Chair: J Franklyn (Birmingham)
|
|
S6
|
A 30-year perspective on radioiodine therapy for nontoxic goitre. From non-acceptance to implementation of rhTSH-augmented therapy
L Hegedüs (Odense, Denmark)
|
| |
|
|
|
17:30 18:05
|
|
Clinical Endocrinology Visiting Professor Lecture
Supported by the Clinical Endocrinology Trust
Main auditorium
Chair: A Weetman (Sheffield)
|
|
S7
|
What have we learned about the management of patients with prolactinomas?
M Molitch (Chicago, USA)
|
| |
|
|
|
18.05 18.30
|
|
Steroid Special Interest Group Satellite reception
A buffet will be available for those attending the satellite
Queen's Suite Foyer
|
| |
|
|
|
18:05 18:35
|
|
Novo Nordisk Satellite reception
A buffet will be available for those attending the satellite
Upper Foyer
|
| |
|
|
|
18:30 18:35
|
|
What the Research Network can do for you
|
|
|
J Wilding (Liverpool)
|
| |
|
|
|
18:35 19:35
|
|
Steroid Special Interest Group Satellite: Measuring steriods - opporunities and pitfalls
Queen's Suite 1
Chairs: A Wallace (Glasgow) & D Grammatopoulos (Warwick)
|
| 18:35 |
|
Pitfalls in measuring testosterone - a US perspective
W Rosner (New York, USA)
|
| 19:00 |
|
Plasma corticosteroid profiling
R Fraser (Glasgow)
|
| 19:25 |
|
Urinary steroid profiling by GC/MS as a diagnostic tool in adrenal disease
W Arlt (Birmingham)
|
| 19:50 |
|
Vitamin D – why move to LC/MS/MS?
A Wallace (Glasgow)
|
| |
|
|
|
18:35 19:35
|
|
Novo Nordisk Satellite: Metabolic syndrome
Main auditorium
Chair: K Boelaert (Birmingham)
|
|
|
A translational journey from L cells to b cells
S Gough (Birmingham)
|
| |
|
|
| Thur 19 March
|
|
07:15 08:00
|
|
Clinical Expert 5: Differential diagnosis of Cushing’s
A Grossman (London)
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: K Meeran (London)
|
| |
|
|
|
07:15 08:00
|
|
Clinical Expert 6: The tired patient
J Miell (London)
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: S Aylwin (London)
|
| |
|
|
|
08:15 08:50
|
|
Society for Endocrinology Medal Lecture
Main auditorium
Chair: D Ray (Manchester)
|
|
S8
|
New genes, new diabetes and new treatments
A Hattersley (Exeter)
|
| |
|
|
|
08:55 09:30
|
|
Clinical Endorinology Trust Lecture
Supported by the Clinical Endocrinology Trust
Main auditorium
Chair: L Rees (London)
|
|
S9
|
The metabolic consequences of pituitary insufficiency
D Johnston (London)
|
| |
|
|
|
09:30 10:00
|
|
Coffee
Hall Q
|
| |
|
|
|
10:00 12:00
|
|
Clinical Management Workshop 3: Endocrine consequences of cancer treatment
Survivorship following cancer, a new endocrine epidemic
Supported by the Clinical Endocrinology
Queen's Suite 1
Chairs: R Ross (Sheffield) & H Spoudeas (London)
|
| 10:00 |
S54
|
Survivorship following cancer - an overview
M Hawkins (Birmingham)
|
| 10:30 |
S55
|
Gonadal function and fertility potential
R Anderson (Edinburgh)
|
| 11:00 |
S56
|
Pituitary and thyroid dysfunction, who gets it, when to test and where?
H Gleeson (Manchester)
|
| 11:30 |
S57
|
Survivorship and Models of Care for Endocrinologists
A Toogood (Birmingham)
|
| |
|
|
|
10:00 12:00
|
|
Clinical Management Workshop 4: Interfaces between endocrinology & internal medicine
Important endocrine consults
Supported by the Clinical Endocrinology
Main auditorium
Chairs: J Bevan (Aberdeen) & A Brooke (London)
|
| 10:00 |
S58
|
Amiodarone-associated hyperthyroidism, a practical guide to investigation and therapy
A Weetman (Sheffield)
|
| 10:30 |
S59
|
Epilepsy in women – what are the endocrine, metabolic and reproductive health considerations?
M Morrell (Stanford, USA)
|
| 11:00 |
S60
|
Iatrogenic adrenal suppression: Diagnosis and management
P Stewart (Birmingham)
|
| 11:30 |
S61
|
Hyponatraemia: investigation and management
C Thompson (Dublin, Ireland)
|
| |
|
|
|
10:00 12:30
|
|
Retired Endocrinologists' session
Chairs: D Anderson (Umbria, Italy) & G Vinson (London)
|
| 10:00 |
S81
|
The adrenal cortex and life
G Vinson (London)
|
| 10:25 |
S82
|
Importance of comparative studies to general understanding of endocrine systems
R Balment (Manchester)
|
| 10:50 |
S83
|
Photoperiodic signalling in birds
P Sharp (Edinburgh)
|
| 11:15 |
S84
|
The use of anabolic steroids in the gym
M Wheeler (Exmouth)
|
| 11:40 |
S85
|
Leadership for creation of excellence
R Dyer (Cambridge)
|
| 12:05 |
S86
|
Jade, Sex and a Chinese Neolithic Culture
D Anderson (Umbria, Italy)
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 3 repeat: Turner Syndrome - how to smooth the transition between paediatric and adult clinic
M Davies (London)
Generously supported by Ipsen Ltd
Queen's Suite 1
Chair: G Conway (London)
|
| |
|
|
|
12:00 12:45
|
|
Clinical Expert 4 repeat: Vitamin D deficiency, diagnosis and management
Z Mughal (Manchester)
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: P Selby (Manchester)
|
| |
|
|
|
12:45 13:30
|
|
Clinical Expert 5 repeat: Differential diagnosis of Cushing’s
A Grossman (London)
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: K Meeran (London)
|
| |
|
|
|
12:45 13:30
|
|
Clinical Expert 6 repeat: The tired patient
J Miell (London)
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: S Aylwin (London)
|
| |
|
|